Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 171 (TMEM171)
- Target
- TMEM171
- Molecular classification
- Transmembrane protein, Other (not classified as receptor, enzyme, channel, transporter, transcription factor, histone-related)
01
Overview
Transmembrane protein 171 (TMEM171) is a protein encoded by the TMEM171 gene in humans, located on chromosome 5q13.2. The longest isoform has 324 amino acids and a molecular weight of ~44 kDa. TMEM171 is predicted to span the plasma membrane with four transmembrane domains, and undergoes several post-translational modifications including glycosylation, N-terminal acetylation, palmitoylation, phosphorylation, and O-β-GlcNAc modification. It interacts with proteins such as MIER1 (a transcriptional repressor), but its overall molecular function and mechanisms remain poorly characterized. TMEM171 exhibits moderate and tissue-differentiated expression, with clinical associations to several cancers. It is evolutionarily conserved in vertebrates, but not classified as a receptor, enzyme, ion channel, transporter, or transcription factor based on current knowledge.
- Other names
- TMEM171PRP2Proline-rich protein PRP2Transmembrane protein 171
02
Mechanism of action
Not applicable; no known drugs interact directly with TMEM171
03
Biological functions
Currently uncharacterized; known to be a membrane-associated proteinDifferential expression in tissues, highest in thyroid, mammary gland, stomach, duodenum, kidneyMay play a role in transcriptional regulation through interaction with MIER1 (transcriptional repressor)Possible cellular localization in plasma membrane
04
Disease associations
Cancer (down-regulated in papillary thyroid carcinoma, colon cancer, gastric cancer; high expression favorable in renal cancer; up-regulated in triple-negative breast cancer cell lines upon TNFα stimulation)Potential risk marker for papillary thyroid carcinoma via SNPs R86G, N139KAutosomal dominant tubulointerstitial kidney disease (bioinformatic association)Phosphoribosylpyrophosphate synthetase superactivity (bioinformatic association)
05
Safety considerations
Not established; TMEM171 is not a known therapeutic target, receptor, or enzyme
06
Interacting drugs
None known or reported in available literature and databases
07
Biomarkers
Down-regulation in papillary thyroid carcinoma, colon cancer, and gastric cancer; high expression in renal cancer associated with favorable prognosisRisk SNPs R86G, N139K as genetic risk markers for papillary thyroid carcinoma
Beyond the preview
Go deeper on Transmembrane protein 171 (TMEM171).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protein 171 (TMEM171).